Quinidine (15% dihydroquinidine)
Based on 24 publication(s) in Google Scholar
Quinidine (15% dihydroquinidine) is an orally active antiarrhythmic agent. Quinidine (15% dihydroquinidine) reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine (15% dihydroquinidine) exerts sustained block and open-channel block effects on IK(f). Quinidine (15% dihydroquinidine) alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine (15% dihydroquinidine) can be used in studies related to uterine sarcoma and seizures.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.36%
- CAS No.: 56-54-2
- 화학식: C20H24N2O2
- 분자량:324.42
-
보관:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Quinidine (15% dihydroquinidine)
More- Nat Commun. 2024 Jun 19;15(1):5230. [Abstract]
- Adv Sci (Weinh). 2025 Aug 19:e05666. [Abstract]
- J Hazard Mater. 2021 Aug 15:416:125764. [Abstract]
- Environ Int. 2019 Jun;127:694-703. [Abstract]
- Anal Chem. 2025 Nov 18;97(45):25158-25167. [Abstract]
- J Med Chem. 2021 Mar 11;64(5):2725-2738. [Abstract]
- J Med Chem. 2020 Oct 8;63(19):11085-11099. [Abstract]
- Environ Pollut. 2024 May 25:124214. [Abstract]
- Pharmaceutics. 2025 Mar 26;17(4):423. [Abstract]
- J Agric Food Chem. 2022 Mar 2;70(8):2520-2528. [Abstract]
- Cell Mol Life Sci. 2025 Nov 25;82(1):419. [Abstract]
- RSC Adv. 2019 May 23;9(28):16136-16146. [Abstract]
- Front Pharmacol. 2020 Jul 31;11:1038. [Abstract]
- Cell Calcium. 2026 Mar:134:103125. [Abstract]
- Virol J. 2024 Aug 8;21(1):181. [Abstract]
- J Anim Sci. 2022 Apr 1;100(4):skac069. [Abstract]
- Andrology. 2025 Oct;13(7):1805-1815. [Abstract]
- AAPS J. 2021 Jun 28;23(4):91. [Abstract]
- Food Chem Toxicol. 2022 Nov:169:113431. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Pharmacol Res Perspect. 2021 Oct;9(5):e00879. [Abstract]
- Pharmacol Res Perspect. 2020 Apr;8(2):e00575. [Abstract]
- Eur J Drug Metab Pharmacokinet. 2022 Sep;47(5):639-652. [Abstract]
- Chemosphere. 2021 Dec:284:131347. [Abstract]
Customer Validation & Images
-
Flow Cytometry
-
Bio/Physico-chemical Assay
-
WB
-
RT-PCR
-
Bio/Physico-chemical Assay
All Caspase Isoforms
More
Biological Activity
|
Caspase 3 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | IC50 |
2.2 μM
Compound: Quinidine
|
TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells
TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells
|
[PMID: 10820137] |
| CHO | IC50 |
6.4 μM
Compound: quinidine
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503] |
| CHO | IC50 |
2.67 μM
Compound: Quinidine
|
Inhibition of human ERG expressed in CHO cells by patch plate method
Inhibition of human ERG expressed in CHO cells by patch plate method
|
[PMID: 26640981] |
| HEK293 | IC50 |
113.8 μM
Compound: quinidine
|
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy
|
[PMID: 18788725] |
| HEK293 | IC50 |
16600 nM
Compound: Quinidine
|
Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA
Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA
|
[PMID: 21300721] |
| HEK293 | IC50 |
19.82 μM
Compound: Quinidine
|
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit
|
[PMID: 22761000] |
| HEK293 | IC50 |
11.2 μM
Compound: quinidine
|
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
|
[PMID: 23241029] |
| HeLa | IC50 |
23.4 μM
Compound: Quinidine
|
TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in OCT1-expressing HeLa cells
TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in OCT1-expressing HeLa cells
|
[PMID: 10027858] |
| Hepatocyte | IC50 |
240 μM
Compound: 14 Quinidine
|
Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes
Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes
|
[PMID: 15225721] |
| Huh-7 | CC50 |
50.75 μM
Compound: GNF-Pf-5459
|
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
|
[PMID: 18579783] |
| LLC-PK1 | IC50 |
10 μM
Compound: Quinidine
|
Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
10 μM
Compound: Quinidine
|
TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells
TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
13 μM
Compound: Quinidine
|
Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
13 μM
Compound: Quinidine
|
TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells
TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
5.6 μM
Compound: Quinidine
|
Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
5.6 μM
Compound: Quinidine
|
TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells
TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells
|
[PMID: 12699389] |
| NIH-3T3-G185 | IC50 |
1 μM
Compound: Quinidine
|
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
18.8 μM
Compound: Quinidine
|
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
33.9 μM
Compound: Quinidine
|
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| ScN2a | IC50 |
5 μM
Compound: quinidine
|
Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation
Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation
|
[PMID: 17850126] |
| Ventricular myocyte | IC50 |
15600 nM
Compound: Quinidine
|
Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes
Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes
|
[PMID: 21300721] |
| Ventricular myocyte | IC50 |
10 μM
Compound: Quinidine
|
Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes
Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes
|
[PMID: 22761000] |
| Ventricular myocyte | IC50 |
15.6 μM
Compound: Quinidine
|
Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes
Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes
|
[PMID: 22761000] |
| WI-38 | IC50 |
11.28 μg/mL
Compound: 1b
|
Cytotoxicity against human WI38 cells by MTT assay
Cytotoxicity against human WI38 cells by MTT assay
|
[PMID: 23816880] |
| WI-38 | IC50 |
34.81 μM
Compound: QND
|
Cytotoxicity against human WI38 cells by MTT assay
Cytotoxicity against human WI38 cells by MTT assay
|
[PMID: 26063305] |
Quinidine (15% dihydroquinidine) (10 μM; 24 h) potentiates Paclitaxel (HY-B0015)-induced cytotoxicity in P-gp-positive MES-SA/DX5 uterine sarcoma cells (reducing paclitaxel IC50 to 80.56 nM) but does not alter paclitaxel cytotoxicity in P-gp-negative MES-SA uterine sarcoma cells[1].
Quinidine (15% dihydroquinidine) (10 μM; 24 h) significantly increases the sub-G1 apoptotic portion in paclitaxel-treated P-gp-positive MES-SA/DX5 uterine sarcoma cells, enhancing paclitaxel-induced apoptosis[1].
Quinidine (15% dihydroquinidine) inhibits the in vitro metabolism of Debrisoquine in rat liver microsomes, with lower potency than observed in human liver microsomes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:P-gp-negative MES-SA uterine sarcoma cells, P-gp-positive MES-SA/DX5 uterine sarcoma cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Did not significantly alter the cytotoxicity of paclitaxel in MES-SA cells, with paclitaxel IC50 remaining comparable to paclitaxel alone (19 nM vs. 18 nM).
Strongly potentiated paclitaxel-induced cytotoxicity in MES-SA/DX5 cells, reducing the IC50 of paclitaxel from 13851 nM to 81 nM.
Showed no significant cytotoxicity up to 100 μM in either cell line.\nShowed concentration-dependent cytotoxicity with docetaxel against MES-SA cells.
Enhanced docetaxel-induced cytotoxicity in MES-SA/DX5 cells more potently than hydrocinchonine, alongside cinchonine.
Showed no significant cytotoxicity up to 100 μM in either cell line.
-
Cell Line:P-gp-positive MES-SA/DX5 uterine sarcoma cells (paclitaxel-treated)
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly increased the sub-G1 apoptotic portion (G0 = 27.19) in paclitaxel-treated MES-SA/DX5 cells, whereas paclitaxel alone induced minimal sub-G1 accumulation (G0 = 0.05).
Quinidine (15% dihydroquinidine) (10-30 mg/kg; intraperitoneal injection; single administration) significantly elevates the threshold of pentylenetetrazol-induced tonic convulsions in male NMRI mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lewis (male, 175-225 g)[3]
-
Dosage:80 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced urinary excretion of p-hydroxyamphetamine to 7.2% of vehicle-control levels in the 0-24 h collection period.
Reduced urinary excretion of p-hydroxyamphetamine to 24.1% of vehicle-control levels in the 24-48 h collection period.
Increased amphetamine excretion to 542% of control levels in the 24-48 h period.
Excreted an average of 0.40 μmol p-hydroxyamphetamine and 7.80 μmol amphetamine in the 0-24 h period.
Excreted an average of 3.60 μmol amphetamine and a significantly reduced amount of p-hydroxyamphetamine relative to controls in the 24-48 h period.
Achieved total combined excretion of amphetamine and p-hydroxyamphetamine over 48 h equal to 79.7% of the administered dose, which was not significantly different from control groups.
-
Animal Model:NMRI (male, 5-6 weeks old, 25-30 g)[4]
-
Dosage:10 mg/kg; 20 mg/kg; 30 mg/kg
-
Administration:i.p.; single dose
-
Result:Did not alter the pentylenetetrazole threshold dose for onset of myoclonic twitch.
Significantly increased the pentylenetetrazole threshold dose for onset of tonic hind limb extension compared to saline-treated controls (p < 0.05).
Chemical Information
-
CAS No. 56-54-2
-
Appearance Solid
-
분자량 324.42
-
화학식 C20H24N2O2
-
Color White to off-white
-
SMILES
C=C[C@H]1C[N@](CC[C@H]1C2)[C@@]2([H])[C@@H](O)C3=CC=NC4=CC=C(OC)C=C34
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)
Publications (24)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Small molecule in situ resin capture provides a compound first approach to natural product discovery. [Abstract]2024 Jun 19;15(1):5230. PMID: 38898025 -
Adv Sci (Weinh)
LPS-Induced Mitochondrial Damage via SLC41A1-Mediated Magnesium Ion Efflux Leads to the Pyroptosis of Dental Stem Cells. [Abstract]2025 Aug 19:e05666. PMID: 40831212
Quinidine (15% dihydroquinidine) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 19:e05666. [Abstract]
Quinidine rescued [Mg2⁺]i levels in LPS‐treated or TRPM7‐silenced DPSCs and SCAP.
-
J Hazard Mater
Stereostructure-activity mechanism of cyproconazole by cytochrome P450 in rat liver microsomes: A combined experimental and computational study. [Abstract]2021 Aug 15:416:125764. PMID: 33827004
Quinidine (15% dihydroquinidine) purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2021 Aug 15:416:125764. [Abstract]
Effects of CYP enzymes inhibitors on metabolic rates of cyproconazole stereoisomers in the in vitro incubation mixtures with RLMs. The asterisks (*) indicates the significant difference in metabolic rates under inhibition compared to the control.
-
Environ Int
2019 Jun;127:694-703. PMID: 30991225
Quinidine (15% dihydroquinidine) purchased from MedChemExpress. Usage Cited in: Environ Int. 2019 Jun;127:694-703. [Abstract]
CYP2D6 has contributed in the enantioselectivity of IFP and ICPO because the EF value of the KND-supplemented group follows a doseeffect relationship and the difference in the EF values was over 10% relative to the DMSO control group.
-
Anal Chem
A Computational Integration Strategy Driven by Chemical Similarity Uncovers Comprehensive Metabolic Profiles of Small Bioactive Peptides via UHPLC-HRMS for Doping Control. [Abstract]2025 Nov 18;97(45):25158-25167. PMID: 41202118 -
J Med Chem
Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration. [Abstract]2021 Mar 11;64(5):2725-2738. PMID: 33619967 -
J Med Chem
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. [Abstract]2020 Oct 8;63(19):11085-11099. PMID: 32886512 -
Environ Pollut
Assessing environmental and human health risks: Insight from the enantioselective metabolism and degradation of fenpropidin. [Abstract]2024 May 25:124214. PMID: 38801883 -
Pharmaceutics
Plasma Protein Binding, Biostability, Metabolite Profiling, and CYP450 Phenotype of TPB15 Across Different Species: A Novel Smoothened Inhibitor for TNBC Therapy. [Abstract]2025 Mar 26;17(4):423. PMID: 40284418 -
J Agric Food Chem
Enantioselective Metabolic Mechanism and Metabolism Pathway of Pydiflumetofen in Rat Liver Microsomes: In Vitro and In Silico Study. [Abstract]2022 Mar 2;70(8):2520-2528. PMID: 35184556 -
Cell Mol Life Sci
2025 Nov 25;82(1):419. PMID: 41288707 -
RSC Adv
Identification of key transporters mediating uptake of aconitum alkaloids into the liver and kidneys and the potential mechanism of detoxification by active ingredients of liquorice. [Abstract]2019 May 23;9(28):16136-16146. PMID: 35521419 -
Front Pharmacol
Eye Drops of Metformin Prevents Fibrosis After Glaucoma Filtration Surgery in Rats via Activating AMPK/Nrf2 Signaling Pathway. [Abstract]2020 Jul 31;11:1038. PMID: 32903813
Quinidine (15% dihydroquinidine) purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Jul 31;11:1038. [Abstract]
Cell cycle relative proteins/genes (CyclinD1, CDK4, P21 and P27) level were assessed in HConFs after Quinidine treatment by western blot.
Quinidine (15% dihydroquinidine) purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Jul 31;11:1038. [Abstract]
Cell cycle relative proteins/genes (CyclinD1, CDK4, P21 and P27) level were assessed in HConFs after Atropine/Quinidine treatment by qRT-PCR.
-
Cell Calcium
MONNA alleviates MPTP-induced Parkinson's disease in zebrafish by activating TFEB dependently on ER Calcium. [Abstract]2026 Mar:134:103125. PMID: 41637953 -
Virol J
2024 Aug 8;21(1):181. PMID: 39118175 -
J Anim Sci
2022 Apr 1;100(4):skac069. PMID: 35247050 -
Andrology
Pharmacological inhibition of KSper impairs flagellar pH homeostasis of human spermatozoa. [Abstract]2025 Oct;13(7):1805-1815. PMID: 39498893 -
AAPS J
Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization. [Abstract]2021 Jun 28;23(4):91. PMID: 34181150 -
Food Chem Toxicol
The "steric-like" inhibitory effect and mechanism of doxycycline on florfenicol metabolism: Interaction risk. [Abstract]2022 Nov:169:113431. PMID: 36116547 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Pharmacol Res Perspect
Effects of membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver of drugs: A microdialysis study in rats. [Abstract]2021 Oct;9(5):e00879. PMID: 34628723 -
Pharmacol Res Perspect
Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats. [Abstract]2020 Apr;8(2):e00575. PMID: 32266794 -
Eur J Drug Metab Pharmacokinet
Evaluation of an Ussing Chamber System Equipped with Rat Intestinal Tissues to Predict Intestinal Absorption and Metabolism in Humans. [Abstract]2022 Sep;47(5):639-652. PMID: 35733077 -
Chemosphere
A proposed "steric-like effect" for the slowdown of enrofloxacin antibiotic metabolism by ciprofloxacin, and its mechanism. [Abstract]2021 Dec:284:131347. PMID: 34323809
용액&용해도
DMSO : ≥ 50 mg/mL (154.12 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 14.29 mg/mL (44.05 mM; ultrasonic and warming and heat to 60°C)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (290 KB)
-
SDS (481 KB)
- English - EN (481 KB)
- Français - FR (481 KB)
- Deutsch - DE (481 KB)
- Norwegian - NO (481 KB)
- Español - ES (481 KB)
- Swedish - SV (481 KB)
- Italian - IT (481 KB)
- Korean - KR (481 KB)
- Portuguese - PT (481 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee SY, et al. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol. 2011 Aug;26(4):424-31. [Content Brief]
[2]. Kehl SJ, et al. Quinidine-induced inhibition of the fast transient outward K+ current in rat melanotrophs. Br J Pharmacol. 1991;103(3):1807-1813. [Content Brief]
[3]. Moody DE, et al. Quinidine inhibits in vivo metabolism of amphetamine in rats: impact upon correlation between GC/MS and immunoassay findings in rat urine. J Anal Toxicol. 1990;14(5):311-317. [Content Brief]
[4]. Jamali H, et al. Effect of dextromethorphan/quinidine on pentylenetetrazole- induced clonic and tonic seizure thresholds in mice. Neurosci Lett. 2020;729:134988. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 3.0824 mL | 15.4121 mL | 30.8242 mL | 77.0606 mL |
| 5 mM | 0.6165 mL | 3.0824 mL | 6.1648 mL | 15.4121 mL | |
| 10 mM | 0.3082 mL | 1.5412 mL | 3.0824 mL | 7.7061 mL | |
| 15 mM | 0.2055 mL | 1.0275 mL | 2.0549 mL | 5.1374 mL | |
| 20 mM | 0.1541 mL | 0.7706 mL | 1.5412 mL | 3.8530 mL | |
| 25 mM | 0.1233 mL | 0.6165 mL | 1.2330 mL | 3.0824 mL | |
| 30 mM | 0.1027 mL | 0.5137 mL | 1.0275 mL | 2.5687 mL | |
| 40 mM | 0.0771 mL | 0.3853 mL | 0.7706 mL | 1.9265 mL | |
| DMSO | 50 mM | 0.0616 mL | 0.3082 mL | 0.6165 mL | 1.5412 mL |
| 60 mM | 0.0514 mL | 0.2569 mL | 0.5137 mL | 1.2843 mL | |
| 80 mM | 0.0385 mL | 0.1927 mL | 0.3853 mL | 0.9633 mL | |
| 100 mM | 0.0308 mL | 0.1541 mL | 0.3082 mL | 0.7706 mL |
Quinidine (15% dihydroquinidine) Related Classifications
HY-B1751 Related Classifications
Powered by Bioz